Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Gastro Hep Advances|August 12, 2024
Rectal Cancer Risk After Colectomy in Patients With Inflammatory Bowel Disease-A Population-Based Danish Cohort Study 1978-2018Elena Akimenko, Jacob Tveiten Bjerrum, Aske Thorn Iversen, et al.
Statistics in Medicine|April 11, 2025
Instrumental Variable Methods to Target Hypothetical Estimands With Longitudinal Repeated Measures Data: Application to the STEP 1 TrialJack Bowden, Jesper Madsen, Bryan Goldman, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|April 22, 2023
Risk of anorectal cancer in patients with Crohn's disease and perianal fistula: a nationwide Danish cohort studyAlaa El-Hussuna, Camilla Engel Lemser, Aske Thorn Iversen, et al.
Obesity (Silver Spring, Md.)|January 5, 2025
Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trialsBeverly G Tchang, Michael G Knight, Kasper Adelborg, et al.
BMJ Open Gastroenterology|April 30, 2024
Risk of cancer in patients with bile acid diarrhoea: a Danish nationwide matched cohort studyNynne Nyboe Andersen, Signe Wildt, Aske Thorn Iversen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2023
Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory DiseasesDaniel Ward, Nynne Nyboe Andersen, Sanne Gørtz, et al.
Epidemiology and Infection|October 22, 2025
COVIDmeter - a questionnaire-based symptom monitoring system for the surveillance of COVID-19 in Denmark, 2020-2023Pernille Kold Munch, Christian Holm Hansen, Frederik Trier Møller, et al.
Obesity (Silver Spring, Md.)|May 17, 2023
Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mgAaron S Kelly, Silva Arslanian, Dan Hesse, et al.
Pageof 1